The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple sclerosis made an important step towards appropriate use of MRI in routine clinical practice. Since their promulgation, there have been substantial relevant advances in knowledge, including the 2017 revisions of the McDonald diagnostic criteria, renewed safety concerns regarding intravenous gadolinium-based contrast agents, and the value of spinal cord MRI for diagnostic, prognostic, and monitoring purposes. These developments suggest a changing role of MRI for the management of patients with multiple sclerosis. This 2021 revision of the previous guidelines on MRI use for patients with multiple sclerosis merges recommendations from the Magnetic Resonance Imaging in Multiple Sclerosis study group, Consortium of Multiple Sclerosis Centres, and North American Imaging in Multiple Sclerosis Cooperative, and translates research findings into clinical practice to improve the use of MRI for diagnosis, prognosis, and monitoring of individuals with multiple sclerosis. We recommend changes in MRI acquisition protocols, such as emphasising the value of three dimensional-fluid-attenuated inversion recovery as the core brain pulse sequence to improve diagnostic accuracy and ability to identify new lesions to monitor treatment effectiveness, and we provide recommendations for the judicious use of gadolinium-based contrast agents for specific clinical purposes. Additionally, we extend the recommendations to the use of MRI in patients with multiple sclerosis in childhood, during pregnancy, and in the post-partum period. Finally, we discuss promising MRI approaches that might deserve introduction into clinical practice in the near future., Competing Interests: Declaration of interests MPW reports personal fees from Novartis, Sanofi Genzyme, Bayer HealthCare Pharmaceuticals, Roche, Biogen, Biologix, Celgene, Merck Serono, Imcyse, IXICO, and Medison and personal fees and non-financial support from Genilac, outside the submitted work. OC reports personal fees from Roche and Merck Serono, outside the submitted work; and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK. DSR is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, part of the US National Institutes of Health, and has also received research support from Vertex Pharmaceuticals. BB reports personal fees from Novartis, UCB Pharmaceuticals, and Roche and non-financial support from Teva Neuroscience, Biogen, and Genentech, outside the submitted work; and is funded by the National MS Society, National Institutes of Health, and Multiple Sclerosis Society of Canada. NdS reports personal fees from Biogen, Genzyme, Merck Serono, Novartis, Roche, Celgene, Teva Pharmaceutical, outside the submitted work; and has received research grant support from the Italian MS Society. CE reports personal fees from Biogen, Bayer HealthCare Pharmaceuticals, Merck Serono, Novartis, Shire, Genzyme, Teva Pharmaceuticals, Sanofi, Celgene, and Roche, outside the submitted work. FF reports personal fees from Biogen, Sanofi Genzyme, Merck Serono, Novartis, Teva Pharmaceuticals, Actelion, MedDay, and Parexel, outside the submitted work. MF reports personal fees from Biogen, Merck Serono, Novartis, and Teva Pharmaceuticals, outside the submitted work; receives research support from Biogen, Merck Serono, Novartis, Teva Pharmaceuticals, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and Fondazione Italiana di Ricerca per la SLA; and is editor-in-chief of the Journal of Neurology. JF reports personal fees from Biogen, Merck Serono, Santhera Pharmaceuticals, Teva Pharmaceuticals, Sanofi, Almirall, Sanofi Genzyme, and Novartis, outside the submitted work. CG reports personal fees from Biogen, Merck Serono, Teva Pharmaceuticals, Sanofi Genzyme, Almirall, Novartis, Roche, and Bayer, outside the submitted work. YH declares no competing interests. LK reports personal fees from Actelion, Addex, Biotica, Celgene Receptos, Sanofi Genzyme, Eli Lilly, Mitsubishi, Ono Pharmaceutical, Pfizer, Sanofi, Santhera Pharmaceuticals, Siemens, Teva Pharmaceuticals, UCB, and XenoPort; grants and personal fees from Bayer HealthCare Pharmaceuticals, Biogen, Merck Serono, and Novartis; and grants from F Hoffmann-La Roche, EU, Innoswiss, Roche Research Foundation, Swiss Multiple Sclerosis Society, and Swiss National Research Foundation, outside the submitted work. DKBL reports personal fees from Academy of Health Care Learning, Biogen, Consortium of MS Centers, and Sanofi Genzyme, outside the submitted work. KM reports personal fees from Siemens and Novartis, outside the submitted work. XM reports personal fees from Actelion, Biogen, Celgene, Sanofi Genzyme, Merck Serono, Novartis, Teva Pharmaceuticals, ExceMed, MS International Federation, and National MS Society, outside the submitted work. SDN reports personal fees from Biogen, Genentech, Celgene, EMD Serono, Gerson Lehrman Group, BioIncept, and MedDay, outside the submitted work; and has received research funding (paid directly to institution) from Biogen, Novartis, Genentech, National Multiple Sclerosis Society, US Department of Defense, and Patient Centered Outcomes Institute. JO reports grants and personal fees from Biogen, Roche, and EMD Serono; and personal fees from Celgene, Novartis, and Sanofi Genzyme, outside the submitted work. JP reports personal fees from Merck Serono, Roche, UCB, Viela Bio, Euroimmun, and MedDay; grants and personal fees from Biogen, Novartis, Teva Pharmaceuticals, Chugai Pharmaceutical, Bayer HealthCare Pharmaceuticals, Alexion, Sanofi Genzyme, MedImmune, Abide ARGENX; grants from Merck Serono, MS Society, Guthrie Jackson Foundation, National Institute for Health Research, Oxford Health Services Research Committee, European Distance and E-Learning Network, Medical Research Council, Grant for Multiple Sclerosis Innovation, John Fell, and Myaware, outside the submitted work; and is partly funded by highly specialised services to run a national congenital myasthenia service and a neuromyelitis service. MAR reports personal fees from Biogen, Novartis, Sanofi Genzyme, Teva Pharmaceuticals, Merck Serono, and Roche, outside the submitted work; and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. JS-G reports grants and personal fees from Sanofi Genzyme; and personal fees from Almirall, Biogen, Celgene, Merck Serono, Novartis, Roche, and Teva Pharmaceuticals, outside the submitted work; and is member of the Editorial Committee of Multiple Sclerosis Journal and director of the Scientific Committee of Revista de Neurologia. MT reports personal fees from Almirall, Biogen, Sanofi Genzyme, Bayer HealthCare Pharmaceuticals, Roche, Biogen, Viela Bio, Merck Serono, and Novartis, outside the submitted work; and is co-editor of Multiple Sclerosis Journal—Experimental, Translational and Clinical. AT reports research grants from Roche and Sanofi Genzyme; and personal fees from Biogen, Consortium of MS Centers, Sanofi Genzyme, Roche, Novartis, and Teva Neuroscience, outside the submitted work. HV reports grants and consulting fees paid directly to their institution from Merck Serono and Novartis, and grants from Teva Pharmaceuticals, outside the submitted work. TY reports personal fees from Biogen, Novartis, Bayer HealthCare Pharmaceuticals, and Hikma, outside the submitted work; and has received research support from Biogen, GlaxoSmithKline, Novartis, and Schering. FB reports personal fees from Bayer, Biogen, Merck Serono, Novartis, Roche, Teva Pharmaceuticals, and IXICO, outside the submitted work; and is supported by the National Institute for Health Research Biomedical Research Centre at University College London Hospitals. AR reports personal fees from Novartis, Sanofi-Genzyme, Bayer, Roche, Biogen, Neurodiem, Bracco, Merck Serono, Teva Pharmaceuticals, and Icometrix; and non-financial support from SyntheticMR, outside the submitted work., (Copyright © 2021 Elsevier Ltd. All rights reserved.)